Florida Senate - 2015 SENATOR AMENDMENT
Bill No. CS for CS for SB 7066
Ì6390820Î639082
LEGISLATIVE ACTION
Senate . House
.
.
.
.
.
—————————————————————————————————————————————————————————————————
—————————————————————————————————————————————————————————————————
Senator Brandes moved the following:
1 Senate Amendment to Amendment (835218)
2
3 Delete lines 77 - 118
4 and insert:
5 Parkinson’s disease, paraplegia, quadriplegia, cachexia, or
6 terminal illness a physical medical condition that chronically
7 produces symptoms of seizures or severe and persistent muscle
8 spasms may recommend order for the patient’s medical use low-THC
9 cannabis to treat such disease, disorder, or condition; or to
10 alleviate symptoms of such disease, disorder, or condition; or
11 to alleviate symptoms caused by a treatment for such disease,
12 disorder, or condition, if no other satisfactory alternative
13 treatment options exist for that patient and all of the
14 following conditions apply:
15 1.(a) The patient is a permanent resident of this state.
16 2.(b) The physician determines that the risks of
17 recommending ordering low-THC cannabis are reasonable in light
18 of the potential benefit for that patient. If a patient is
19 younger than 18 years of age, a second physician must concur
20 with this determination, and such determination must be
21 documented in the patient’s medical record.
22 3.(c) The physician registers the patient, the patient’s
23 legal representative if requested by the patient, and himself or
24 herself as the recommender orderer of low-THC cannabis for the
25 named patient on the compassionate use registry maintained by
26 the department and updates the registry to reflect the contents
27 of the recommendation order. If the patient is a minor, the
28 physician must register a legal representative on the
29 compassionate use registry. The physician shall deactivate the
30 patient’s registration when treatment is discontinued.
31 4.(d) The physician maintains a patient treatment plan that
32 includes the dose, route of administration, planned duration,
33 and monitoring of the patient’s symptoms and other indicators of
34 tolerance or reaction to the low-THC cannabis.
35 5.(e) The physician submits the patient treatment plan, as
36 well as any other requested medical records, biannually
37 quarterly to the University of Florida College of Pharmacy for
38 research on the safety and efficacy of low-THC cannabis on
39 patients pursuant to subsection (8).
40 6.(f) The physician obtains the voluntary informed consent
41 of the patient or the patient’s legal guardian to treatment with
42 low-THC cannabis after sufficiently explaining the current state
43 of knowledge in the medical community of the effectiveness of
44 treatment of the patient’s conditions or symptoms condition with
45 low-THC cannabis, the medically acceptable alternatives, and the
46 potential risks and side effects.
47 7. For a patient who does not have a condition or symptom
48 other than severe and persistent nausea, seizures, or muscle
49 spasms, a second physician recommends the patient’s medical use
50 of low-THC cannabis.
51 8. For a patient who does not have a condition or symptom
52 other than severe and persistent pain, a second physician who is
53 a board-certified pain management physician, as defined in s.
54 456.44, recommends the patient’s medical use of low-THC
55 cannabis.